Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Trial to Evaluate Vaxart Human Papillomavirus (HPV) Vaccine for the Treatment of Human Papillomavirus (HPV)–Associated Cancer and Dysplasia

Next Previous
Trial Profile

A Clinical Trial to Evaluate Vaxart Human Papillomavirus (HPV) Vaccine for the Treatment of Human Papillomavirus (HPV)–Associated Cancer and Dysplasia

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine (Primary)
  • Indications Cancer; Cervical cancer; Cervical dysplasia; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors Vaxart

    • Most Recent Events

    • 08 Aug 2019 According to a Vaxart media release, the company plans to file human papilloma virus (HPV) Investigational New Drug application (IND) in 2020.
    • 10 Dec 2018 New trial record
    • 09 Nov 2018 According to a Vaxart media release, the company is advancing its first therapeutic vaccine (Vaxart HPV vaccine) for the treatment of human papillomavirus (HPV)-associated cancer and dysplasia, and is on track to file an IND for the HPV vaccine in 2019.Preparations to advance this program into the clinic in 2019 are underway.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top